Projects and registries
Ongoing projects and registries
TITLE
MEPOLIZUMAB IN EGPA
PROMOTER/PI
Prof Giacomo Emmi, University of Florence and Dr. Alvise Berti, University of Trento and Dr. Roberto Padoan, University of Padua, Italy
AIM
1) the long-term follow-up of patients treated with Mepo (following the study published by Bettiol et al A&R 2022), also expanding the cohort of patients on Mepo 300mg (Leading center: Firenze, Italy)
2) the effectiveness and safety of switching from Mepolizumab 100 to 300mg/4 weeks or vice versa (Leading center: Firenze, Italy)
3) the effectiveness and safety of Mepo 300mg/4 weeks in newly diagnosed EGPA: The MEPEARL – MEPolizumab in EgpA Real Life study (PI Roberto Padoan, Padova, Italy)
4) the influence of anthropometric features on the response to Mepo (PI Alvise Berti, Trento, Italy)
TITLE
Mepolizumab before Benralizumab
PROMOTER/PI
Prof Giacomo Emmi, University of Florence, Italy
AIM
To assess the effectiveness and safety on patients treated with Benralizumab after a previous Mepolizumab treatment
TITLE
Tezepelumab and EGPA
PROMOTER/PI
Prof Benjamin Terrier, Cochin Hospital, Paris, France
AIM
This study will allow to collect retrospectively the off-label use of Tezepelumab (anti-TSLP) for the treatment of relapsing and/or refractory EGPA.
TITLE
Overlapping forms of PR3-ANCA EGPA/GPA
PROMOTER/PI
Prof Benjamin Terrier, Cochin Hospital, Paris, France
AIM
This study will allow to better characterise the presentation, course and therapeutic management of overlapping forms of EGPA/GPA with PR3-ANCA
TITLE
Ophthalmic vascular manifestations related to hypereosinophilia
PROMOTER/PI
Matthieu Groh, Internal Medicine Department, CEREO (Reference coordinating center of hypereosinophilic syndrome in France) – Foch Hospital
AIM
The topic is ophthalmic vascular manifestations(central retinal artery occlusion, central retinal vein occlusion, Purtscher’s retinopathy or retinal vasculitis) related to hypereosinophilia.
Study design: retrospective observational multi-centre
Inclusion criteria:
(i) at least one episode of ophthalmic vascular manifestation (CRAO, branch retinal artery occlusion (BRAO), CRVO, branch retinal vein occlusion (BRVO), Purtscher retinopathy, retinal vasculitis or ION);
(ii) concomitant absolute eosinophilia count (AEC) ≥ 0.5 x109 /L when the ophthalmic vascular manifestation occurred.
Exclusion criteria are: any condition, comorbidity or concomitant treatment leading to (constitutional or acquired) thrombophilia, cardiac embolism, rhythmic heart disease, tight carotid stenosis (NASCET ≥70%) homolateral to the retinal involvement or other causes of Purtscher’s retinopathy (e.g. acute pancreatitis, head trauma or thrombotic microangiopathy) or ION (e.g. giant cell arteritis).
TITLE
Therapeutic approaches in myeloperoxidase (MPO)-associated interstitial lung disease (ILD): a multicentre study
PROMOTER/PI
Giacomo Emmi, University of Firenze, Italy
AIM
– To investigate the pattern of use of different treatments (immunosuppressants, anti-fibrotics or their combination) in patients with MPO-associated ILD
– To investigate the effectiveness of immunosuppressants (+/- anti-fibrotic agents) vs anti-fibrotic agents in patients with MPO-associated ILD.
– To assess the rate of acute exacerbations following remission during treatment with immunosuppressants (+/- anti-fibrotic agents) vs anti-fibrotic agents;
– To assess the occurrence of AAV during treatment with immunosuppressants (+/- anti-fibrotic agents) vs anti-fibrotic agents;
– To assess potential differences in term of prognosis (hospitalization, death) in patients receiving immunosuppressants (+/- anti-fibrotic agents) vs anti-fibrotic agents;
– To assess the safety of the treatment with immunosuppressants (+/- anti-fibrotic agents) vs anti-fibrotic agents
TITLE
Efficacy and safety of Rituximab in EPGA patients with renal involvement
PROMOTER/PI
Dario Roccatello, University of Torino, Italy
AIM
TITLE
EGPA onset during biologic treatment for severe asthma
PROMOTER/PI
Marco Caminati, University of Verona, Italy
AIM
To assess the prevalence of EGPA onset during the course of biologic treatment with anti-IL-5, anti-IgE or anti IL-4/IL-13 treatments, prescribed for severe asthma.
TITLE
Effectiveness and Safety of Benralizumab in patients with EGPA: a retrospective study
PROMOTER/PI
Giacomo Emmi and Augusto Vaglio, University of Firenze, Italy
AIM
To investigate retrospectively the efficacy and safety of benralizumab in EGPA patients.
TITLE
Effectiveness and Safety of Benralizumab in patients with EGPA: a retrospective study
PROMOTER/PI
Giacomo Emmi and Augusto Vaglio, University of Firenze, Italy
AIM
To investigate retrospectively the efficacy and safety of benralizumab in EGPA patients.
TITLE
Eosinophilia-related temporal arteritis
PROMOTER/PI
Prof Benjamin Terrier, Cochin Hospital, Paris, France
AIM
This study will allow to specify the existence or not of an eosinophilic temporal arteritis, whose characteristics and prognosis could differ from giant cell arteritis. Also, the therapeutic management could be specified.
TITLE
Impact of mepolizumab on patient-reported outcomes in eosinophilic granulomatosis with polyangiitis by using ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire: the faster the better?
PROMOTER/PI
Sara Monti and Paolo Delvino, University of Pavia, Italy
AIM
To assess the effect of mepolizumab on patient-reported outcomes in patients with refractory ENT manifestations and/or asthma secondary to EGPA by using the AAV PRO questionnaire.
TITLE
Long-term outcomes of patients with coronary spasm associated with eosinophilia: the SPASMEO multicentric retrospective study
SCIENTIFIC DIRECTOR
Dr Matthieu Groh, Internal Medicine Department, CEREO (Reference coordinating center of hypereosinophilic syndrome in France) – Foch Hospital
AIM
– To set up the first international multicentric cohort of patients with eosinophilia-associated coronary vasospasms to provide an in- depth report of the clinical picture and MRI findings of EGPA
– To estimate survival rates, shed light on predictors of relapse
– Eventually, to provide a practical data-driven therapeutic algorithm for EGPA.
INTERVIEW BY THE EXPERTS
